

Antibacterial Resistance Leadership Group (ARLG)

Emerging *S. aureus* Antimicrobial Resistance and Current Prescribing Practices for Patients Presenting to US Emergency Departments with a Purulent Skin and Soft Tissue Infection

1/17/2023

Jesus R. Torres, MD, MPH, MSc Assistant Professor of Emergency Medicine David Geffen School of Medicine at UCLA





Disclosures

ARLG EVERYONE grant

Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI104681. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health

- EMERGEncy IDNET
 - Grant number: U01CK000643
- No conflicts of interest



Background

- Purulent Skin and soft tissue infections (SSTIs)
 - 5.4 million to 8.4 million ED/clinic visits in 2015¹







Background

- CA-MRSA emergence¹
 - 17% MSSA
 - 59% MRSA
 - 97% USA300

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Methicillin-Resistant S. aureus Infections among Patients in the Emergency Department

Gregory J. Moran, M.D., Anusha Krishnadasan, Ph.D.,
Rachel J. Gorwitz, M.D., M.P.H., Gregory E. Fosheim, M.P.H.,
Linda K. McDougal, M.S., Roberta B. Carey, Ph.D., and David A. Talan, M.D.,
for the *EMERGE*ncy ID Net Study Group*


- CA-MRSA antibiotic sensitivity
 - 95% Clindamycin
 - 92% Tetracycline
 - 100% Trimethoprim-sulfamethoxazole



Background

- 2014 IDSA SSTI Guideline³
 - TMP/SMX or Doxycycline


- National Survey 2016⁴
 - 7.5 Million TMP/SMX
 - 4.5 Million Tetracyclines
 - 3.3 Million Clindamycin





Background: Emergence of resistance?


- National Database Analysis⁵
 - MRSA and MSSA TMP/SMX resistance





Background: Emergence of resistance?


- Pediatric population 2005-2017⁶
 - TMP/SMX resistance 2% to 13%





Background: Changing epidemiology?

- 2006 MRSA isolates: USA300 (CC8)
- 2022 –TMP/SMX resistance genes: CC398





Background: Changing epidemiology?






CHOOSING WISELY RECOMMENDATIONS

Avoid antibiotics and wound cultures in emergency department patients with uncomplicated skin and soft tissue abscesses after successful incision and drainage and with adequate medical follow-up.



Objectives

- Primary Objective
 - MRSA and MSSA resistance to
 - TMP/SMX
 - Tetracycline
 - Clindamycin





Objectives

- Secondary Objectives
 - MRSA and MSSA prevalence
 - Risk factors for TMP/SMX S. aureus resistance
 - Frequency of culture and sensitivity testing
 - Types of antibiotics prescribed
 - Genetic typing of a subset of TMP/SMX resistant samples



Methods

- Prospective, multicenter, observational
- Inclusion Criteria
 - Any age
 - Purulent SSTI ≤ 7 days
 - Skin abscess
 - Infected wounds



Methods

Exclusion Criteria

- Perirectal abscesses
- Mammalian bites
- Suspected osteomyelitis or septic arthritis
- Unable to provide consent
- Psychiatric holds
- Prisoners



Methods: Sites



Sites

- Brigham and Women's Hospital
- Hennepin County Medical Center
- Johns Hopkins Medical Center
- Lewis Katz School of Medicine at Temple University
- Valleywise Medical Center
- Oregon Health Sciences University
- University of Iowa
- University of New Mexico Health Sciences Center
- University of Mississippi Medical Center
- University of Missouri-Kansas City
- Olive View-UCLA Medical Center
- Ronald Reagan UCLA Medical Center



Methods

- Sample size: 437
- 6-month enrollment period
 - May to October 2024
- Follow up
 - 1 Month follow up telephone call

Baseline/Enrollment Form (BEF) Clinician questions:
1. Type of purulent skin and soft tissue infection: Skin abscess (If more than one abscess, how many present: Infected wound Purulent cellulitis Surgical site infection
2. Duration of symptoms (circle number of days): 1 2 3 4 5 6 7
3. Is there tenderness to palpation of SSTI? $\ \square$ Yes $\ \square$ No
4. Is there swelling associated with the SSTI? $\ \square$ Yes $\ \square$ No
5. From the largest lesion, estimate the maximal width and length of:
5a. Erythema: Width cm Length cm
5b. <u>Induration</u> : Width cm Length cm
5c. Fluctuance: Width cm Length cm



Methods: Lab

- Would Cultures
 - Central Laboratory
 - Cultures and Sensitivity
 - Genetic typing of a subset of TMP/SMX resistant



Future

- Inform current clinical practice
- Glimpse of the circulating variants



Citations

- 1. Fritz S, Shapiro DJ, Hersh A. National trends in incidence of purulent skin and soft tissue infections in patients presenting to ambulatory and emergency department settings, 2000–2015. *Clin Infect Dis.* 2020:70:2715-8.
- Moran GJ, Krishnadasan A, Gorwitz RJ, et al. EMERGEncy ID Net Study Group.
 Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355:666-74.
- 3. Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59:e10-52.
- 4. Storandt MH, Walden CD, Sahmoun AE, Beal JR. Trends and risk factors in the antibiotic management of skin and soft tissue infections in the United States. *J Dermatolog Treat*. 2022;33:1576-80.
- 5. Ham DC, Fike L, Wolford H, et al. Trimethoprim-sulfamethoxazole resistance patterns among *Staphylococcus aureus* in the United States, 2012-2018. *Infect Control Hosp Epidemiol*. 2022;5:1-4.
- 6. Khamash DF, Voskertchian A, Tamma PD, et al. Increasing clindamycin and trimethoprim-sulfamethoxazole resistance in pediatric *Staphylococcus aureus* infections. *J Pediatric Infect Dis Soc.* 2019;8:351-3.
- Slides 3 & 10 pictures form uptodate



The Team!

Special thanks to my mentors:

Dr. David Talan

Dr. Gregory Moran

Dr. Anusha Krishnadasan









Questions

Thank you!

